@prefix dcterms: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix obo: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix hasPart: . @prefix sfam: . @prefix ProteinComplex: . @prefix go: . @prefix hasAgent: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasPart: sub:_2, sub:_3; a ProteinComplex: . sub:_2 geneProductOf: hgnc:12774; a Protein: . sub:_3 geneProductOf: sfam:FZD%20Family; a Protein: . sub:_4 hasAgent: sub:_5; a go:0016301 . sub:_5 geneProductOf: hgnc:3236; a Protein: . sub:_6 hasAgent: sub:_7; a go:0016301 . sub:_7 geneProductOf: sfam:MAPK%20Erk1%2F2%20Family; a Protein: . sub:_8 rdf:object sub:_6; rdf:predicate belv:increases; rdf:subject sub:_4; a rdf:Statement . sub:_9 occursIn: obo:UBERON_0002367, species:9606; rdf:object sub:_8; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "complex(p(HGNC:WNT1),p(SFAM:\"FZD Family\")) -> (kin(p(HGNC:EGFR)) -> kin(p(SFAM:\"MAPK Erk1/2 Family\")))", "kin(p(HGNC:EGFR)) -> kin(p(SFAM:\"MAPK Erk1/2 Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_11; pav:version "20131211" . sub:_10 prov:value "Recent studies from our laboratory [63] have shown that treatment of mammary epithelial cells with Wnt-1 or Wnt-5a activates ErbB1 and the MAPK cascade. The effect is rapid and can be blocked by an ErbB1 mAb that interferes with ligand binding, or by metalloproteinase inhibitors. These results suggest that in a manner similar to that described for GPCR agonists, Wnt binding to Fz transactivates ErbB1 by increasing the availability of an ErbB1 ligand. Interestingly, Wnt-transactivated ErbB1 was responsible for MAPK activation and for the increased levels of cyclin D1 that were found in Wnt-1-expressing cells."; prov:wasQuotedFrom pubmed:12648469 . sub:_11 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12648469; prov:wasDerivedFrom beldoc:, sub:_10 . } sub:pubinfo { this: dcterms:created "2014-07-03T14:32:00.292+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }